Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
367 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,282 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02778308 | Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma | completed | N/A | 100 | Govind Ballabh Pant Institute of Postgraduate Medical Education and ResearchOTHER_GOV | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04801719 | Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis | completed | N/A | 76 | Brno University HospitalOTHER | 1 | Mar 17, 2021 |
| NCT02692911 | Chile Biliary Longitudinal Study | completed | — | 4,749 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2021 | clinicaltrials |
| NCT03405909 | Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study(ESCULAP) | completed | — | 517 | University Hospital ErlangenOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT03338062 | A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy | completed | N/A | 15 | Indiana UniversityOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT03778593 | FOLFIRINOX for 2nd-line Treatment of BTC | completed | Phase 2 | 34 | Dong-A University HospitalOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03830606 | The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | completed | Phase 2 | 54 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03307538 | Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma(STRONG) | completed | N/A | 6 | Erasmus Medical CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT03613168 | Trastuzumab in HER2-positive Biliary Tract Cancer(BILHER) | completed | Phase 2 | 4 | Changhoon YooOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02579616 | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy | completed | Phase 2 | 29 | Eisai Co., Ltd.INDUSTRY | 1 | Dec 23, 2020 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03438435 | Fluorescence QRH-882260 Peptide Imaging in the Bile Duct | completed | Phase 1 | 1 | D. Kim Turgeon, MDOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03231176 | Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer | completed | Phase 2 | 62 | ASLAN PharmaceuticalsOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | completed | Phase 1 / Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01844245 | Endobiliary RFA for Unresectable Malignant Biliary Strictures | completed | N/A | 174 | Bing HuOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT01247337 | Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma | completed | Phase 2 | 56 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04568512 | DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture(DNA) | completed | N/A | 67 | Mahidol UniversityOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01938729 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02428855 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03411200 | Patient Activation Through Counseling, Exercise and Mobilization(PACE-Mobil) | completed | N/A | 99 | Herlev and Gentofte HospitalOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT04385147 | Advanced Endoscopy During COVID-19 | completed | — | 670 | Al-Azhar UniversityOTHER | 5 | Jul 8, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT00339560 | A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China | completed | — | 2,624 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03027284 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | completed | Phase 1 | 79 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT00948935 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | completed | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02456714 | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma(4CC) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01347333 | Stereotactic Body Radiotherapy for Liver Tumors | completed | N/A | 23 | Mercy ResearchOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01256047 | Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy | completed | Phase 4 | 40 | Chiba UniversityOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT00779454 | Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | completed | Phase 2 | 72 | Vejle HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT03267966 | Margin Status After Pancreaticoduodenectomy for Cancer | completed | N/A | 168 | Campus Bio-Medico UniversityOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers(ABC06) | completed | Phase 3 | 162 | The Christie NHS Foundation TrustOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02496741 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors(MACIST) | completed | Phase 1 / Phase 2 | 15 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02730611 | Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma(METSLIVER) | completed | — | 124 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02592538 | Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma | completed | N/A | 66 | First People's Hospital of HangzhouOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01900158 | A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas | completed | Phase 1 | 24 | PCI Biotech ASINDUSTRY | 4 | Oct 29, 2019 | clinicaltrials |
| NCT02773459 | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 31 | Seoul National University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT04072250 | Surgery for Recurrent Intrahepatic Cholangiocarcinoma | completed | — | 216 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT02425137 | A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 2 | 51 | TTY BiopharmINDUSTRY | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02002806 | Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control | completed | N/A | 150 | Indiana UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT02841800 | Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis | completed | N/A | 5 | National Taiwan University HospitalOTHER | 0 | Aug 5, 2019 | clinicaltrials |
| NCT03150615 | Enteral Nutrition After Pancreaticoduodenectomy | completed | N/A | 120 | Nanjing Medical UniversityOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT01766219 | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 17 | Wake Forest University Health SciencesOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02000999 | Diagnosis of Bile Duct Strictures | completed | — | 110 | Washington University School of MedicineOTHER | 1 | May 13, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | completed | Phase 2 | 39 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01917617 | Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer | completed | Phase 2 | 50 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | Feb 21, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2021source: clinicaltrials